Regencell Bioscience Holdings Stock Statistic Functions Beta

RGC Stock  USD 23.10  -0.56  -2.37%   
The statistic functions module provides an execution environment for Beta function and related indicators on Regencell Bioscience. Signals here center on statistical functions describing dispersion and variability alongside volatility and performance references.Please specify Time Period to run the technical study.

The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Regencell Bioscience correlated with the market. If Beta is less than 0 Regencell Bioscience generally moves in the opposite direction as compared to the market. If Regencell Bioscience Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Regencell Bioscience is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Regencell Bioscience is generally in the same direction as the market. If Beta > 1 Regencell Bioscience moves generally in the same direction as, but more than the movement of the benchmark.

Regencell Bioscience Technical Analysis Modules

Most technical analysis of Regencell Bioscience help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Regencell from various momentum indicators to cycle indicators. When you analyze Regencell charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Regencell Bioscience Holdings Ltd

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine bioscience company. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. Regencell Bioscience operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. The profile for Regencell Bioscience integrates fundamentals, price behavior, and sector exposure. Market-sensitive characteristics amplify cycle exposure. Regencell Bioscience has a market cap of 12.12 B, P/E of 26.21, ROE of -54.81%.

Methodology

Unless otherwise specified, financial data for Regencell Bioscience Holdings is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Regencell (USA Stocks:RGC) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Macroaxis analytics incorporate public filings and market reference sources and official disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Data harmonization may result in minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Regencell Bioscience Holdings is covered by 15 analysts. 7 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Evercore ISI, Morgan Stanley, BMO Capital Markets, Oppenheimer & Co., Guggenheim Securities, HSBC Global Research, among others. Updates may occur throughout the day.


Become your own money manager

Tracking Regencell Bioscience inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.

Did you try this?

Run Premium Stories Now

   

Premium Stories

Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
All  Next Launch Module

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Baby Boomer Prospects Idea
Baby Boomer Prospects
Invested over 20 shares
Momentum Idea
Momentum
Invested over 40 shares
FinTech Idea
FinTech
Invested over 60 shares
Impulse Idea
Impulse
Invested over 200 shares
Investor Favorites Idea
Investor Favorites
Invested few shares
Macroaxis Index Idea
Macroaxis Index
Invested over 60 shares
Hedge Favorites Idea
Hedge Favorites
Invested few shares
Warren Buffett Holdings Idea
Warren Buffett Holdings
Invested over 20 shares
Blockchain Idea
Blockchain
Invested few shares
Driverless Cars Idea
Driverless Cars
Invested few shares

More Resources for Regencell Stock Analysis

A structured review of Regencell Bioscience often starts with core financial statements and trend context. Ratios and trend metrics help frame Regencell Bioscience's operating context. Key reports that frame Regencell Bioscience Holdings Stock are listed below:
Regencell Bioscience has a market cap of 12.12 B, ROE of -54.81%. Use Your Equity Center to explore allocation context. This includes a position in Regencell Bioscience Holdings in the portfolio view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
Analysis related to Regencell Bioscience should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
 Earnings Share
-0.01
 Return On Assets
-0.33
 Return On Equity
-0.55
The market value of Regencell Bioscience is measured differently than book value, which reflects Regencell accounting equity. Regencell Bioscience's market capitalization is 12.12 B. With a P/B ratio of 2492.65, the market values Regencell Bioscience well above its book equity. Enterprise value stands at 12.11 B. Intrinsic value is an analytical estimate of Regencell Bioscience's underlying worth that can differ from price and book value. Valuation methods help interpret those gaps.
Note that Regencell Bioscience's intrinsic value and market price are different measures derived from different inputs. For Regencell Bioscience, key inputs include a P/E ratio of 26.21, a P/B ratio of 2492.65, and ROE of -54.81%. Market price reflects the current exchange level formed by active bids and offers.